A novel intracellular role of matrix metalloproteinase-3 during apoptosis of dopaminergic cells

Journal of Neurochemistry

Volumn 106, Issue 1, 2008, Pages 405-415

  Choi, Dong Hee ^a   Kim, Eun Mee ^a   Son, Hyo Jin ^a   Joh, Tong H ^a   Kim, Yoon Seong ^b   Kim, Donghou ^a,c   Flint Beal, M ^b   Hwang, Onyou ^a,c  

^a University of Ulsan College of Medicine   (South Korea)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c Asan Institute for Life Sciences   (South Korea)

Author keywords

Apoptotic signaling; Dopaminergic neuron; Matrix metalloproteinase 3; Parkinson's disease; Tetrahydrobiopterin

Indexed keywords

CASPASE 3; DNA FRAGMENT; SMALL INTERFERING RNA; STRESS ACTIVATED PROTEIN KINASE; STROMELYSIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CATALYSIS; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME REPRESSION; FEMALE; GENE EXPRESSION; MALE; MOLECULAR WEIGHT; NERVE CELL CULTURE; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; WILD TYPE;

ANIMALS; APOPTOSIS; CATALYTIC DOMAIN; CELL LINE; CELLS, CULTURED; CYTOPROTECTION; DOPAMINE; ENZYME ACTIVATION; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; INTRACELLULAR FLUID; MATRIX METALLOPROTEINASE 3; MICE; MICE, KNOCKOUT; MITOGEN-ACTIVATED PROTEIN KINASE 8; NERVE DEGENERATION; NEURONS; PARKINSON DISEASE; RATS; RATS, SPRAGUE-DAWLEY; RNA INTERFERENCE; SERINE ENDOPEPTIDASES; SUBSTANTIA NIGRA;

ANIMALIA;

EID: 45249115717     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2008.05399.x     Document Type: Article

References (48)

1. Anastasiadis P. Z., Jiang H., Bezin L., Kuhn D. M. Levine R. A. (2001) Tetrahydrobiopterin enhances apoptotic PC12 cell death following withdrawal of trophic support. J. Biol. Chem. 276, 9050 9058.
2. Cao J., Rehemtulla A., Pavlaki M., Kozarekar P. Chiarelli C. (2005) Furin directly cleaves proMMP-2 in the trans-Golgi network resulting in a nonfunctioning proteinase. J. Biol. Chem. 280, 10974 10980.
3. Cauwe B., Van den Steen P. E. Opdenakker G. (2007) The biochemical, biological, and pathological kaleidoscope of cell surface substrates processed by matrix metalloproteinases. Crit. Rev. Biochem. Mol. Biol. 42, 113 185.
4. Chandler S., Miller K. M., Clements J. M., Lury J., Corkill D., Anthony D. C., Adams S. E. Gearing A. J. (1997) Matrix metalloproteinases, tumor necrosis factor and multiple sclerosis: an overview. J. Neuroimmunol. 72, 155 161.
5. Choi H. J., Jang Y. J., Kim H. J. Hwang O. (2000) Tetrahydrobiopterin is released from and causes preferential death of catecholaminergic cells by oxidative stress. Mol. Pharmacol. 58, 633 640.
6. Choi H. J., Kim S. W., Lee S. Y. Hwang O. (2003a) Dopamine-dependent cytotoxicity of tetrahydrobiopterin: a possible mechanism for selective neurodegeneration in Parkinson's disease. J. Neurochem. 86, 143 152.
7. Choi H. J., Kim S. W., Lee S. Y., Moon Y. W. Hwang O. (2003b) Involvement of apoptosis and calcium mobilization in tetrahydrobiopterin-induced dopaminergic cell death. Exp. Neurol. 181, 281 290.
8. Choi H. J., Lee S. Y., Cho Y. Hwang O. (2004) JNK activation by tetrahydrobiopterin: implication for Parkinson's disease. J. Neurosci. Res. 75, 715 721.
9. Choi H. J., Lee S. Y., Cho Y. Hwang O. (2005) Inhibition of vesicular monoamine transporter enhances vulnerability of dopaminergic cells: relevance to Parkinson's disease. Neurochem. Int. 46, 329 335.
10. Choi H. J., Lee S. Y., Cho Y., No H., Kim S. W. Hwang O. (2006) Tetrahydrobiopterin causes mitochondrial dysfunction in dopaminergic cells: implications for Parkinson's disease. Neurochem. Int. 48, 255 262.
11. +), oxidant and specific neurotoxicants shares the common molecular mechanism. J. Neurochem. 76, 1010 1021.
12. Crocker S. J., Pagenstecher A. Campbell I. L. (2004) The TIMPs tango with MMPs and more in the central nervous system. J. Neurosci. Res. 75, 1 11.
13. Hammani K., Henriet P. Eeckhout Y. (1992) Cloning and sequencing of a cDNA encoding mouse stromelysin 1. Gene 120, 321 322.
14. Han J. M., Lee Y. J., Lee S. Y., Kim E. M., Moon Y., Kim H. W. Hwang O. (2007) Protective effect of Sulforaphane against dopaminergic cell death. J. Pharmacol. Exp. Ther. 321, 249 256.
15. Herron G. S., Werb Z., Dwyer K. Banda M. J. (1986) Secretion of metalloproteinases by stimulated capillary endothelial cells. I. Production of procollagenase and prostromelysin exceeds expression of proteolytic activity. J. Biol. Chem. 261, 2810 2813.
16. Kim S. W., Jang Y. J., Chang J. W. Hwang O. (2003) Degeneration of the nigrostriatal pathway and induction of motor deficit by tetrahydrobiopterin: an in vivo model relevant to Parkinson's disease. Neurobiol. Dis. 13, 167 176.
17. Kim S. T., Chang J. W., Hong H. N. Hwang O. (2004) Loss of striatal dopaminergic fibers after intraventricular injection of tetrahydrobiopterin in rat brain. Neurosci. Lett. 359, 69 72.
18. Kim S. T., Choi J. H., Chang J. W., Kim S. W. Hwang O. (2005a) Immobilization stress causes increases in tetrahydrobiopterin, dopamine, and neuromelanin and oxidative damage in the nigrostriatal system. J. Neurochem. 95, 89 98.
19. Kim Y. S., Kim S. S., Cho J. J., Choi D. H., Hwang O., Shin D. H., Chun H. S., Beal M. F. Joh T. H. (2005b) Matrix metalloproteinase-3: a novel signaling proteinase from apoptotic neuronal cells that activates microglia. J. Neurosci. 25, 3701 3711.
20. Kim Y. S., Choi D. H., Block M. L. et al. (2007) A pivotal role of matrix metalloproteinase-3 activity in dopaminergic neuronal degeneration. FASEB J. 21, 179 187.
21. Kirsch M., Korth H. G., Stenert V., Sustmann R. de Groot H. (2003) The autoxidation of tetrahydrobiopterin revisited. Proof of superoxide formation from reaction of tetrahydrobiopterin with molecular oxygen. J. Biol. Chem. 278, 24481 24490.
22. Lee S. Y., Moon Y. H., Choi D. H., Choi H. J. Hwang O. (2007) Particular vulnerability of rat mesencephalic dopaminergic neurons to tetrahydrobiopterin: implications for Parkinson's disease. Neurobiol. Dis. 25, 112 120.
23. Leist M. Jaattela M. (2001) Four deaths and a funeral: from caspases to alternative mechanisms. Nat. Rev. Mol. Cell. Biol. 2, 589 598.
24. Li D. Q., Shang T. Y., Kim H. S., Solomon A., Lokeshwar B. L. Pflugfelder S. C. (2003) Regulated expression of collagenases MMP-1, -8, and -13 and stromelysins MMP-3, -10, and -11 by human corneal epithelial cells. Invest. Ophthalmol. Vis. Sci. 44, 2928 2936.
25. Liao J., Wolfman J. C. Wolfman A. (2003) K-ras regulates the steady-state expression of matrix metalloproteinase 2 in fibroblasts. J. Biol. Chem. 278, 31871 31878.
26. Lijnen H. R. (2002) Matrix metalloproteinases and cellular fibrinolytic activity. Biochemistry 67, 92 98.
27. Lohi J., Wilson C. L., Roby J. D. Parks W. C. (2001) Epilysin, a novel human matrix metalloproteinase (MMP-28) expressed in testis and keratinocytes and in response to injury. J. Biol. Chem. 276, 10134 10144.
28. Luo D., Mari B., Stoll I. Anglard P. (2002) Alternative splicing and promoter usage generates an intracellular stromelysin 3 isoform directly translated as an active matrix metalloproteinase. J. Biol. Chem. 277, 25527 25536.
29. MacPherson L. J., Bayburt E. K., Capparelli M. P. et al. (1997) Discovery of CGS 27023A, a non-peptidic, potent, and orally active stromelysin inhibitor that blocks cartilage degradation in rabbits. J. Med. Chem. 40, 2525 2532.
30. Marchenko G. N. Strongin A. Y. (2001) MMP-28, a new human matrix metalloproteinase with an unusual cysteine-switch sequence is widely expressed in tumors. Gene 265, 87 93.
31. Masserano J. M., Gong L., Kulaga H., Baker I. Wyatt R. J. (1996) Dopamine induces apoptotic cell death of a catecholaminergic cell line derived from the central nervous system. Mol. Pharmacol. 50, 1309 1315.
32. Miyazaki I., Asanuma M., Diaz-Corrales F. J., Fukuda M., Kitaichi K., Miyoshi K. Ogawa N. (2006) Methamphetamine-induced dopaminergic neurotoxicity is regulated by quinone-formation-related molecules. FASEB J. 20, 571 573.
33. Mudgett J. S., Hutchinson N. I., Chartrain N. A. et al. (1998) Susceptibility of stromelysin 1-deficient mice to collagen-induced arthritis and cartilage destruction. Arthritis Rheum. 41, 110 121.
34. Nakanishi H. (2003) Microglial functions and proteases. Mol. Neurobiol. 27, 163 176.
35. O'Connell A. R. Stenson-Cox C. (2007) A more serine way to die: defining the characteristics of serine protease-mediated cell death cascades. Biochim. Biophys. Acta 1773, 1491 1499.
36. Pei D. Weiss S. J. (1995) Furin-dependent intracellular activation of the human stromelysin 3 zymogen. Nature 375, 244 247.
37. Pei D. Weiss S. J. (1996) Transmembrane-deletion mutants of the membrane-type matrix metalloproteinase-1 process progelatinase A and express intrinsic matrix-degrading activity. J. Biol. Chem. 271, 9135 9140.
38. Rosenberg G. A. (2002) Matrix metalloproteinases in neuroinflammation. Glia 39, 279 291.
39. Sternlicht M. D. Werb Z. (2001) How matrix metalloproteinases regulate cell behavior. Annu. Rev. Cell. Dev. Biol. 17, 463 516.
40. St-Pierre Y., Van Themsche C. Estève P. O. (2003) Emerging features in the regulation of MMP-9 gene expression for the development of novel molecular targets and therapeutic strategies. Curr. Drug Targets Inflamm. Allergy 2, 206 215.
41. Suri C., Fung B. P., Tischler A. S. Chikaraishi D. M. (1993) Catecholaminergic cell lines from the brain and adrenal glands of tyrosine hydroxylase-SV40 T antigen transgenic mice. J. Neurosci. 13, 1280 1291.
42. Troy C. M. Salvesen G. S. (2002) Caspases on the brain. J. Neurosci. Res. 69, 145 150.
43. Velasco G., Pendás A. M., Fueyo A., Knäuper V., Murphy G. López-Otín C. (1999) Cloning and characterization of human MMP-23, a new matrix metalloproteinase predominantly expressed in reproductive tissues and lacking conserved domains in other family members. J. Biol. Chem. 274, 4570 4576.
44. Westermarck J. Kahari V. M. (1999) Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J. 13, 781 792.
45. Wilhelm M., Xu Z., Kukekov N. V., Gire S. Greene L. A. (2007) Proapoptotic Nix activates the JNK pathway by interacting with POSH and mediates death in a Parkinson disease model. J. Biol. Chem. 282, 1288 1295.
46. Woessner J. F. Nagase H. (2000) Matrix Metalloproteinases and TIMPs. Oxford University Press, Oxford, UK.
47. Yong V. W. (2005) Metalloproteinases: mediators of pathology and regeneration in the CNS. Nat. Rev. Neurosci. 6, 931 944.
48. Yong V. W., Krekoski C. A., Forsyth P. A., Bell R. Edwards D. R. (1998) Matrix metalloproteinases and diseases of the CNS. Trends Neurosci. 21, 75 80.